{"organizations": [], "uuid": "9b95c0bbf264309857731a1aa0f48920b71e8666", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180326.html", "section_title": "Archive News &amp; Video for Monday, 26 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biohaven-says-achieved-both-co-pri/brief-biohaven-says-achieved-both-co-primary-regulatory-endpoints-in-two-pivotal-phase-3-trials-of-rimegepant-idUSASC09TJV", "country": "US", "domain_rank": 408, "title": "BRIEF-Biohaven Says Achieved Both Co-Primary Regulatory Endpoints In Two Pivotal Phase 3 Trials Of Rimegepant", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.523, "site_type": "news", "published": "2018-03-26T15:05:00.000+03:00", "replies_count": 0, "uuid": "9b95c0bbf264309857731a1aa0f48920b71e8666"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biohaven-says-achieved-both-co-pri/brief-biohaven-says-achieved-both-co-primary-regulatory-endpoints-in-two-pivotal-phase-3-trials-of-rimegepant-idUSASC09TJV", "ord_in_thread": 0, "title": "BRIEF-Biohaven Says Achieved Both Co-Primary Regulatory Endpoints In Two Pivotal Phase 3 Trials Of Rimegepant", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-biohaven says achieved both co-primary regulatory endpoints in two pivotal phase", "sentiment": "negative"}, {"name": "reuters) - biohaven pharmaceutical holding company ltd", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:\n* BIOHAVEN ANNOUNCES SUCCESSFUL ACHIEVEMENT OF BOTH CO-PRIMARY REGULATORY ENDPOINTS IN TWO PIVOTAL PHASE 3 TRIALS OF RIMEGEPANT AN ORAL CGRP RECEPTOR ANTAGONIST FOR THE ACUTE TREATMENT OF MIGRAINE\n* RESULTS ARE STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL ACROSS MULTIPLE OUTCOME MEASURES\n* EFFICACY AND SAFETY RESULTS WERE CONSISTENT ACROSS BOTH PHASE 3 TRIALS.\n* ON SCHEDULE TO SUBMIT AN NDA FOR RIMEGEPANT IN 2019â€‹ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-26T15:05:00.000+03:00", "crawled": "2018-03-27T12:11:07.001+03:00", "highlightTitle": ""}